On Monday, Zoetis Inc’s (NYSE:ZTS) third-quarter 2024 adjusted EPS increased 16% year over year to $1.58, beating the consensus of $1.46. The animal health firm reported sales of $2.39 billion, up 11%, beating the consensus of $2.29 billion. On an operational basis, revenue for the third quarter of 2024 increased 14% compared with the third quarter of 2023. Also Read: Elanco’s Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy “Building on the strong momentum from the first half of the year, we are proud to have delivered another excellent…